{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:45:45Z","timestamp":1791755145134,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ygyno.2026.08.023","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:23:39Z","timestamp":1791231819000},"page":"109-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Farletuzumab ecteribulin, a folate receptor alpha (FR\u03b1) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1\/2 dose-finding study"],"prefix":"10.1016","volume":"213","author":[{"given":"Robert M.","family":"Wenham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alejandro","family":"Perez-Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau Guill\u00e9n","family":"Sent\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Guerra Alia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Follana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Eberst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Sebastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalyn","family":"Hawk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.08.023_bb0005","unstructured":"International Agency for Research on Cancer (IARC), Cancer Tomorrow. Globocan 2022 (version 1.1): incidence. https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/tables?cancers=24_25&single_unit=10000&years=2050&types=0 (accessed 3 March 2026)."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0010","unstructured":"International Agency for Research on Cancer (IARC), Cancer Tomorrow. Globocan 2022 (version 1.1): mortality. https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/tables?cancers=24_25&single_unit=10000&years=2050&types=1 (accessed 3 March 2026)."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115222","article-title":"Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0020","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms25021046","article-title":"Folate receptor alpha\u2014a novel approach to cancer therapy","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0025","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41388-025-03448-3","article-title":"Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment","volume":"44","author":"Narayana","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0030","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1535-7163.MCT-24-0763","article-title":"Advances in antibody-drug conjugates for endometrial cancer","volume":"24","author":"Tu","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0035","series-title":"Elahere (mirvetuximab soravtansine-gynx) [prescribing information]","year":"2025"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0040","unstructured":"Elahere 5 mg\/mL concentrate for solution for infusion [summary of product characteristics], AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0045","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0050","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0055","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age","volume":"17","author":"Liu","year":"2025","journal-title":"MAbs"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2026.08.023_bb0060","doi-asserted-by":"crossref","first-page":"S671","DOI":"10.1016\/j.annonc.2025.08.1707","article-title":"Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC) [abstract]","volume":"36","author":"Ray-Coquard","year":"2025","journal-title":"Ann. Oncol."},{"issue":"16 Suppl","key":"10.1016\/j.ygyno.2026.08.023_bb0065","article-title":"Safety and efficacy of BAT8006, a folate receptor \u03b1 (FR\u03b1) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: update on the dose optimization\/expansion cohort of BAT-8006-001-CR trial [abstract]","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2026.08.023_bb0070","doi-asserted-by":"crossref","first-page":"S669","DOI":"10.1016\/j.annonc.2025.08.1705","article-title":"First-in-human study of AZD5335, a folate receptor \u03b1 (FR\u03b1)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer [abstract]","volume":"36","author":"Oaknin","year":"2025","journal-title":"Ann. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2026.08.023_bb0075","article-title":"A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer [abstract]","volume":"35","author":"Lee","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0085","article-title":"Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"16 Suppl","key":"10.1016\/j.ygyno.2026.08.023_bb0095","article-title":"Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GTC1184\u201301 study [abstract]","volume":"43","author":"Winer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0100","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","article-title":"MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FR\u03b1 farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity","volume":"17","author":"Cheng","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0105","series-title":"Halaven (Eribulin Mesylate) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0110","unstructured":"Halaven 0.44 mg\/ml solution for injection [summary of product characteristics], Eisai GmbH, Frankfurt am Main, Germany,"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0115","author":"Eisai Co., Ltd."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0120","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/cas.14898","article-title":"Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models","volume":"112","author":"Furuuchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0125","first-page":"538","article-title":"Preclinical and early clinical development of MORAb-202, a folate receptor alpha-targeted antibody-drug conjugate, which utilizes Halaven as payload at first time","volume":"36","author":"Uenaka","year":"2021","journal-title":"Bio Clinica"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0130","doi-asserted-by":"crossref","unstructured":"Y. Zhang, S. Li, T. Uenaka, K. Furuuchi, K. Yonemori, T. Shimizu, et al., Phase I biomarker analysis results of MORAb-202 (farletuzumab ecteribulin) effects on vascular remodeling and immune modulation in patients with ovarian cancer [abstract], Eur. J. Cancer 174(Suppl 1) (2022) S88. Abstract 244 (PB024). https:\/\/doi.org\/10.1016\/S0959-8049(22)01032-2.","DOI":"10.1016\/S0959-8049(22)01032-2"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0135","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1535-7163.MCT-25-0035","article-title":"Antitumor effect of farletuzumab ecteribulin in molecular subtypes of endometrial cancer patient-derived xenograft models","volume":"24","author":"Yagishita","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0140","article-title":"Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: phase I expansion results","author":"Yonemori","year":"2025","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jcph.6187","article-title":"Pharmacokinetic and exposure-response modeling support body surface area-based dosing of farletuzumab ecteribulin in Japanese patients with solid tumors","volume":"65","author":"Hayato","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0155","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0160","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2026.08.023_bb0170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2026.08.023_bb0175","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0090-8258(21)00717-4","volume":"162","author":"Herzog","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2169\/internalmedicine.2779-19","article-title":"Eribulin-induced interstitial pneumonia: a case series and retrospective cohort study","volume":"59","author":"Murakami","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.ygyno.2026.08.023_bb0185","series-title":"Open-label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer","author":"Wenham","year":"2025"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:06:26Z","timestamp":1791752786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S0090825826021153"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farletuzumab ecteribulin, a folate receptor alpha (FR\u03b1) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1\/2 dose-finding study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eisai Inc. and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}